Adare Pharma Solutions is a specialized CDMO that helps pharmaceutical and biotech companies develop oral solid dosage forms. It offers proprietary technologies for taste masking, customized drug release, solubility enhancement, and patient‑centric dosage forms, providing end‑to‑end services from early‑stage research through GMP pilot and commercial manufacturing, along with analytical, regulatory, packaging, and logistics support.
Funding
$35M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Pharmaceutical companies often face difficulties developing oral solid dosage forms that meet patient needs for taste, swallowing ability, solubility, and controlled release, especially for pediatric, geriatric, and high‑potency drugs. These challenges can delay product launch, increase formulation costs, and reduce patient adherence.
Solution
Adare Pharma Solutions operates as a specialized contract development and manufacturing organization (CDMO) focused on oral formulation challenges. It offers proprietary technologies for taste masking, customized drug release, solubility enhancement, and patient‑centric dosage forms such as orally disintegrating tablets and Parvulet® pellets. The company provides end‑to‑end services from early‑stage non‑GMP research through GMP pilot and commercial production, supported by in‑house analytical, stability, and regulatory expertise. Integrated packaging, serialization, and global logistics enable seamless scale‑up and market entry.
Target Audience
Primary customers are pharmaceutical and biotech companies developing oral solid dosage forms, especially those targeting pediatric, geriatric, high‑potency, or poorly soluble drug candidates.
Features
- Microcaps® and Optimµm® physical barrier technologies delivering precise taste masking, customizable release profiles, and high coating efficiency
- Precision Particle Fabrication™ for uniform microspheres and microcapsules with tunable particle size (150‑200 µm) and dose flexibility
- Customized release platforms (multiparticulates, mini‑tablets, matrix tablets, functional coatings) providing a wide range of release kinetics and dosage forms
- Solubility enhancement via solid‑solution/dispersions (Diffucaps®), spray‑drying, hot‑melt, and cyclodextrin‑based approaches to improve bioavailability and reduce food effects
- Patient‑centric dosage technologies (Parvulet®, AdvaTab® ODT) designed for pediatric, geriatric and dysphagic populations
- Dedicated high‑potency handling suite and small‑scale non‑GMP laboratory for rapid early‑stage development
- Comprehensive analytical services including method development, GMP testing, stability studies under ICH conditions, and advanced instrumentation (UPLC/MS/MS, DSC, particle sizing, microscopy)
- Full regulatory support and technology transfer capabilities from R&D through commercial manufacturing